Evidence map›Paper›PMID 37799973›Full record

ArticleFrontiers in pharmacology2023

Synthesis and biological evaluation of novel 1,2,3-triazole hybrids of cabotegravir: identification of potent antitumor activity against lung cancer.

Yajie Guo, Dan Sang, Bin Guo, Dan Wang, Xinyue Xu, Huili Wang, Cuilan Hou, Longfei Mao, Fang Li, Sanqiang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yajie Guo *Department of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Dan Sang *Department of Endocrinology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Bin Guo *Ultrasonic Department, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Dan WangSchool of Public Health, Southern Medical University, Guangzhou, China.
Xinyue XuSchool of Public Health, University of South China, Hengyang, Hunan, China.
Huili WangUniversity of North Carolina Hospitals, Chapel Hill, NC, United States.
Cuilan HouDepartment of Cardiology, Shanghai Children's Hospital, Shanghai Jiaotong University, Shanghai, China.
Longfei MaoCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.
Fang LiHainan Women and Children's Medical Center, Affliated Children's Hospital of Hainan Medical University, Haikou, Hainan Province, China.
Sanqiang LiCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In pursuit of discovering novel anticancer agents, we designed and synthesized a series of novel 1,2,3-triazole hybrids based on cabotegravir analogues. These compounds were subjected to initial biological evaluations to assess their anticancer activities against non-small-cell lung cancer (NSCLC). Our findings indicated that some of these compounds exhibited promising antitumor abilities against H460 cells, while demonstrated less efficacy against H1299 cells. Notably, compound

Indexed as

1,2,3-triazolesanticancerapoptosiscabotegravirlung cancerROS

Identifiers

PMID37799973
PMCPMC10547880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.